<?xml version="1.0" encoding="UTF-8"?>
<ref id="B25">
 <label>25</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wang</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Munoz</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Goy</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Locke</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Jacobson</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Hill</surname>
    <given-names>B</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma</article-title>. 
  <source>N Engl J Med</source> (
  <year>2020</year>) 
  <volume>382</volume>(
  <issue>14</issue>):
  <page-range>1331–42</page-range>.  
  <pub-id pub-id-type="doi">10.1056/NEJMoa1914347</pub-id>
 </mixed-citation>
</ref>
